Biomea Fusion Inc (BMEA)

Biomea Fusion commenced dosing the first patient in Phase II clinical trials COVALENT-211 and COVALENT-212 on March 31, 2026. On March 24, 2026, the company reported its full-year 2025 financial results, showing a significantly reduced net loss, leading to a positive market reaction. Biomea Fusion presented Phase II COVALENT-111 data in Type 2 Diabetes at a conference on March 14, 2026. The company outlined its execution priorities for 2026 on January 12, 2026, focusing on key milestones for icovamenib and BMF-650. On November 4, 2025, Biomea Fusion reported its third-quarter 2025 financial results, demonstrating a year-over-year decrease in operating expenses and a reduced net loss, along with positive 52-week follow-up results from its Phase II COVALENT-111 study. Biomea Fusion unveiled promising preclinical data for icovamenib and introduced BMF-650 on November 15, 2024.

As a clinical-stage biopharmaceutical company without commercialized products, Biomea Fusion does not have direct demand seasonality. Any seasonality would likely relate to stock performance fluctuations influenced by clinical trial milestones, regulatory updates, or financial reporting cycles.

Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on developing oral covalent small molecule drugs for metabolic diseases like diabetes and obesity. Their lead candidate, icovamenib, is being investigated for type 1 and type 2 diabetes, while BMF-650 is a next-generation oral small-molecule GLP-1 receptor agonist for obesity and other metabolic disorders.

Biomea Fusion, Inc. is a U.S.-based company with its headquarters in Redwood City, California. Its operations and clinical trials are primarily focused within the United States.

Biomea Fusion's brand reputation was impacted by an FDA clinical hold on icovamenib trials due to liver toxicity concerns, leading to a stock price drop. The FDA lifted the hold after reviewing clinical data, and positive 52-week follow-up data from the Phase II COVALENT-111 study and the advancement of BMF-650 have positively contributed to the company's reputation.

Biomea Fusion, Inc.'s ownership is a mix of institutional, insider, and retail investors. Institutional investors hold a significant percentage of the stock, with major shareholders including Fmr Llc and Vanguard Group Inc. Individual investors, including co-founders Thomas Butler and Rainer M. Erdtmann, also hold stakes, with Thomas Butler being the largest individual shareholder.